Quantumzyme Corp. (OTC: QTZM), a biotransformation company specializing in sustainable enzyme-based solutions, announced continued progress on strategic initiatives including a planned 4-for-1 forward stock split and the near-completion of its corporate name change to Quantum Genesis AI Corp. These moves aim to better position the company for its next phase of development by recalibrating its capital structure and reflecting its focus on AI-driven enzyme innovation.
The company's Board of Directors has authorized a 4-for-1 forward stock split of its issued and outstanding common stock. The forward split is intended to enhance Quantumzyme's public market profile by providing greater flexibility in its share structure, supporting administrative efficiency in trading, and aligning its public share profile with its current stage of development. However, the forward split will be submitted for processing only after the completion of the pending corporate name and trading symbol change.
As previously disclosed, Quantumzyme is in the final stages of changing its name to Quantum Genesis AI Corp., a change that underscores its strategic focus on advancing enzyme innovation through artificial intelligence, computational modeling, and data-driven research. The company anticipates that the name and corresponding trading symbol change will be completed in the near term. Immediately following the effectiveness of the new name and symbol, Quantumzyme intends to submit the forward stock split to the Financial Industry Regulatory Authority (FINRA) in accordance with applicable regulatory requirements.
Naveen Kulkarni, President of Quantumzyme Corp., stated, “Our planned corporate rebranding and capital structure initiatives are intended to better align the Company’s public market profile with its long-term strategic direction. Completing the name and symbol change first establishes a clear foundation, and, subject to regulatory review, the proposed forward stock split is designed to support a more efficient and accessible public share structure as we continue executing on our technology and operational roadmap.”
If approved, the forward stock split will increase the number of outstanding shares while proportionally adjusting the per-share trading price. The company believes this action may provide several potential benefits, including increased flexibility to support future corporate initiatives. Quantumzyme emphasizes that the forward split is not intended to, and will not by itself, change the company's overall market capitalization. The split will not affect the proportional ownership interests of existing shareholders, except for minor adjustments resulting from the treatment of fractional shares.
The planned forward stock split remains subject to regulatory review and approval, and there can be no assurance regarding the timing or completion of the split. The company expects to provide additional updates regarding the effectiveness of the corporate name and symbol change, as well as the timing and status of the forward stock split submission and review process, through subsequent public disclosures.
For more information, visit www.quantumzymecorp.com and the company's profile at www.otcmarkets.com/stock/QTZM.
